Physician profile
Bette Kim
NPI 1023095171
$2,362.63
in general payments reported to CMS, 2019-2025
15 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $259 · 2021: $176 · 2022: $832 · 2023: $433 · 2024: $304 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $711.57 | 2021-2025 | Camzyos, Eliquis |
| Lantheus Medical Imaging, INC. | $515.59 | 2019-2025 | Definity |
| Cvrx, INC. | $494.40 | 2022-2023 | Barostim Neo System |
| Bardy Diagnostics, INC. | $152.73 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $64.81 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $64.79 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.12 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $61.13 | 2019-2025 | Wainua |
| Merck Sharp & Dohme LLC | $45.07 | 2021-2025 | Verquvo |
| Amgen INC. | $43.07 | 2019-2020 | |
| Philips North America LLC | $39.99 | 2022 | |
| Novo Nordisk INC | $27.95 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $27.74 | 2021 | |
| Pfizer INC. | $27.18 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bette Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.